Biotech Industry Balances Growth Amid Financing Pressures and Patent Cliffs
Event summary
- Biotech revenue grew 12% in 2025, marking the third consecutive year of growth.
- Biotech financing raised US$68.5 billion in 2025, up 11% from 2024, with late-stage VC investments dominating.
- M&A activity rebounded in early 2026, with deal value accounting for 36% of 2025's total.
- Oncology and neurology led M&A by deal value, with US$16.8 billion and US$14.4 billion respectively in deals over US$1 billion.
- The IPO market declined 47% in 2025 but showed signs of recovery in early 2026.
The big picture
The biotech industry continues to demonstrate resilience amid macroeconomic uncertainty and financing pressures. The shift toward late-stage VC investments and targeted M&A deals highlights a strategic pivot to balance growth with risk management. The industry's ability to adapt to emerging challenges, such as patent cliffs and regulatory shifts, will be critical in maintaining its momentum.
What we're watching
- Financing Dynamics
- How the shift toward late-stage VC investments will affect early-stage biotech funding and innovation.
- M&A Strategy
- Whether the focus on targeted acquisitions over megamergers will sustain long-term growth.
- Regulatory Shifts
- The pace at which regulatory changes and domestic manufacturing pledges will impact supply chains and costs.
Related topics